Management and Supportive Care Measures of Adverse Events (AEs) in Higher-Risk MDS Patients (Pts) Treated with Azacitidine (AZA)

被引：0
|
作者：
Santini, Valeria [1 ]
Fenaux, Pierre [2 ]
Mufti, Ghularn J. [3 ]
Hellstrom-Lindberg, Eva [4 ]
Silverman, Lewis B. [5 ]
List, Alan [6 ]
Gore, Steven D. [7 ]
Seymour, John F. [8 ]
Backstrom, Jay [9 ]
McKenzie, David [9 ]
Beach, C. L. [9 ]
机构：
[1] Azienda Osped Careggi, Florence, Italy
[2] Univ Paris 13, Hop Avicenne, AP HP, Hematol Clin, Bobigny, France
[3] Kings Coll London, Dept Haematol Med, London, England
[4] Karolinska Univ Hosp, Stockholm, Sweden
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA
[7] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA
[8] Peter MacCallum Canc Inst, Dept Haematol, Melbourne, Vic, Australia
[9] Celgene, Overland Pk, KS USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：583 / 584
页数：2
相关论文
共 50 条
  • [21] High Healthcare Utilization and Costs in Patients with Higher-Risk MDS/Low Blast Count AML Treated with Azacitidine in Ontario, Canada
    Mozessohn, Lee
    Cheung, Matthew
    Mittmann, Nicole
    Earle, Craig C.
    Liu, Ning
    Buckstein, Rena
    BLOOD, 2018, 132
  • [22] Healthcare utilization in patients with higher-risk MDS/low-blast count AML treated with azacitidine in the 'real-world'
    Mozessohn, Lee
    Cheung, Matthew C.
    Mittmann, Nicole
    Earle, Craig C.
    Liu, Ning
    Buckstein, Rena
    LEUKEMIA & LYMPHOMA, 2020, 61 (06) : 1445 - 1454
  • [23] Bone Marrow Hypocellularity Does Not Impair the Tolerability or Efficacy of Azacitidine (AZA) in Patients with Higher-Risk Myelodysplastic Syndromes Treated in the AZA-001 Study
    Seymour, John F.
    Bennett, John M.
    List, Alan F.
    Mufti, Ghulam J.
    Gore, Steven D.
    Fenaux, Pierre
    Santini, Valeria
    Hetzer, Joel
    Songer, Stephen
    Skikne, Barry S.
    Beach, C. L.
    BLOOD, 2012, 120 (21)
  • [24] Re-Evaluation of the Efficacy of Azacitidine (AZA) In Patients From the AZA-001 Study with Higher-Risk Myelodysplastic Syndromes (MDS) Classified by WHO Criteria and WPSS Risk.
    Gattermann, Norbert
    Sanz, Guillermo F.
    Giagounidis, Aristoteles
    Seymour, John F.
    Fenaux, Pierre
    Santini, Valeria
    Mufti, Ghulam J.
    Muus, Petra
    Ramos, Fernando
    Lucy, Lela M.
    Beach, C. L.
    Silverman, Lewis R.
    BLOOD, 2010, 116 (21) : 1643 - 1644
  • [25] Influence of Karyotype On Overall Survival in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Azacitidine or a Conventional Care Regimen
    Mufti, Ghulam J.
    Gore, Steven D.
    Santini, Valeria
    Fenaux, Pierre
    Silverman, Lewis R.
    Hagemeijer, Anne
    Skikne, Barry
    Hellstrom-Lindberg, Eva
    Seymour, John F.
    Beach, C. L.
    Backstrom, Jay
    Fernando, Indrasiri
    BLOOD, 2009, 114 (22) : 697 - 698
  • [26] Management of haematological adverse events in MDS patients treated with lenalidomide
    Giagounidis, A.
    Cazzola, M.
    Fenaux, P.
    Mufti, G.
    Muus, P.
    Platzbecker, U.
    Sanz, G.
    Cripe, L.
    Von Lilienfeld-Toal, M.
    Wells, R.
    LEUKEMIA RESEARCH, 2007, 31 : S121 - S121
  • [27] Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?
    Amer M. Zeidan
    Maximilian Stahl
    Michelle DeVeaux
    Smith Giri
    Scott Huntington
    Nikolai Podoltsev
    Rong Wang
    Xiaomei Ma
    Amy J. Davidoff
    Steven D. Gore
    Blood Cancer Journal, 8
  • [28] WT1 evaluation in higher-risk myelodysplastic syndrome patients treated with azacitidine
    Falconi, Giulia
    Fabiani, Emiliano
    Ottone, Tiziana
    Piciocchi, Alfonso
    Lavorgna, Serena
    Criscuolo, Marianna
    Fianchi, Luana
    Gurnari, Carmelo
    Postorino, Massimiliano
    Picardi, Alessandra
    Palmieri, Raffaele
    Lo-Coco, Francesco
    Voso, Maria Teresa
    LEUKEMIA & LYMPHOMA, 2020, 61 (04) : 979 - 982
  • [29] Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?
    Zeidan, Amer M.
    Stahl, Maximilian
    DeVeaux, Michelle
    Giri, Smith
    Huntington, Scott
    Podoltsev, Nikolai
    Wang, Rong
    Ma, Xiaomei
    Davidoff, Amy J.
    Gore, Steven D.
    BLOOD CANCER JOURNAL, 2018, 8
  • [30] Relationship among gene methylation, azacitidine treatment, and survival in patients with higher-risk myelodysplastic syndromes (MDS): results from the AZA-001 trial
    Herman, James G.
    Gore, Steven
    Mufti, Ghulam
    Fenaux, Pierre
    Santini, Valeria
    Silverman, Lewis
    Seymour, John
    Griffiths, Elizabeth
    Caraway, Hetty
    MacBeth, Kyle
    McKenzie, David
    Backstrom, Jay
    Beach, C. L.
    CANCER RESEARCH, 2009, 69
12345